6 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
registration strategy to bring the best regimens to HBV patients
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
ratio of 0.08, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
VIR
15 Mar 24
of 0.08, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
regarding Vir's strategy and plans; the potential benefits, safety and efficacy of tobevibart and elebsiran for the treatment of chronic hepatitis delta
10g47pnm9 q9eyeg3252x6bh3t7xl0avmm
VIR
22 Feb 24
of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir's strategy and plans
- Prev
- 1
- Next